Context Therapeutics (CNTX) vs NewcelX (NCEL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
NewcelX (NCEL) has outperformed Context Therapeutics (CNTX) over the past year, losing 22.3% versus a loss of 85.3%. Over five years, CNTX leads with a -96.9% price change compared with -99.7% for NCEL. Context Therapeutics is the larger company by market cap ($14.7 million vs $14.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CNTX | NCEL |
|---|---|---|
| Share price | $0.16 | $2.54 |
| Market cap | $14.70M | $14.67M |
| 1-day change | -5.10% | -5.58% |
| YTD return | -89.12% | +33.68% |
| 1-year return | -85.32% | -22.32% |
| 5-year return | -96.86% | -99.65% |
| P/E ratio (TTM) | — | 4.88 |
| EPS (TTM) | $-0.46 | $0.52 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-36.12M | $-8.30M |
| 52-week high | $3.62 | $5.12 |
| 52-week low | $0.153 | $1.83 |
| Distance from 52-week high | -95.58% | -50.39% |
| Analyst consensus | none | none |
| Avg. price target upside | +2418.75% | +805.51% |
| Average volume | 1.42M | 13.34K |
| Shares outstanding | 91.88M | 5.78M |
| Employees | 15 | 9 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NCEL has outperformed CNTX by 63.0 percentage points over the past year.
About Context Therapeutics
CNTX stock →Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of solid tumors. The company's product candidate includes CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
Health Care · Biotechnology: Pharmaceutical Preparations · 15 employees
About NewcelX
NCEL stock →NewcelX Ltd., a biopharmaceutical company, engages in developing transformative stem-cell-derived therapies for Diabetes. The company develops NCEL-101, a cellular therapy product based on enriched pancreatic islet-like clusters for the treatment of Type 1 diabetes and Type 2 insulin dependent diabetes; AstroRx, an off-the-shelf cryopreserved cell therapy product for the treatment of Amyotrophic Lateral Sclerosis and neurodegenerative indications; and Dual Orexin-Receptor Agonist (DOXA), a small molecules platform for the treatment of sleep disorders, Neurodegenerative/ neuroinflammation diseases, and Diabetes Associated Neurological Disorders.
Health Care · Biotechnology: Pharmaceutical Preparations · 9 employees
CNTX vs NCEL FAQ
Which is bigger, Context Therapeutics or NewcelX?
Context Therapeutics (CNTX) is larger, with a market capitalization of $14.70M compared with $14.67M for NewcelX (NCEL).
Which stock has performed better over the past year, CNTX or NCEL?
NCEL returned -22.32% over the past 12 months, compared with -85.32% for CNTX (price return, excluding dividends). Past performance does not predict future results.
Are Context Therapeutics and NewcelX in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.